Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Decision Resources Group
Introduction of Extended RAS Testing and Recent Clinical Trial Data Will Affect How Physicians Treat Colorectal Cancer Patients, According to Findings from Decision Resources Group
BURLINGTON, Mass., Aug. 28, 2014 /PRNewswire/ -- Decision Resources Group finds that the market for colorectal cancer (CRC) therapies will remain constant, at around $7.7 billion by 2023 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The biosimilar erosion of Roche/Genentech/Chugai's Avastin and Bristol-Myers Squibb/Eli Lilly/Merck KGaA's Erbitux will be balanced out by the launch of Eli Lilly's Cyramza, Taiho Pharmaceutical's Lonsurf, Alchemia's HA-irinotecan and Boehringer Ingelheim's Vargatef, as well as increased uptake of Sanofi/Regeneron's Zaltrap and Amgen/Takeda's Vectibix.
Other key findings from the Pharmacor report entitled Colorectal Cancer:
Comments from Decision Resources Group Analyst Dan Roberts, Ph.D.:
About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources Group
©2012 PR Newswire. All Rights Reserved.
7831 N. Business Park Drive